Skip to main content

Table 1 Patient demographics and baseline characteristics, ITT population

From: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

 

VI 25 mcg OD (N = 115)

SAL 50 mcg BD (N = 116)

Placebo (N = 116)

Total (N = 347)

Age, years

41.0 (17.81)

41.1 (16.84)

41.7 (16.64)

41.3 (17.06)

Female sex, n (%)

68 (59)

77 (66)

59 (51)

204 (59)

Duration of asthma, years

17.61 (13.54)

19.41 (14.87)

18.43 (13.33)

18.49 (13.91)

Screening pre-bronchodilator FEV1 (ml)

2133 (631.4)

2078 (591.7)

2204 (653.0)

2139 (626.2)

Screening % predicted FEV1

66.6 (12.84)

65.8 (12.72)

65.9 (12.03)

66.1 (12.50)

Screening % reversibility FEV1

28.2 (16.36)

26.2 (13.82)

30.0 (16.58)

28.1 (15.67)

Screening absolute FEV1 reversibility (ml)

577.1 (344.79)

533.7 (313.85)

650.6 (383.34)

587.2 (350.84)

Baseline pre-dose FEV1 (ml)

2264 (619.7)

2174 (587.7)

2250 (704.0)

2229 (637.9)

Baseline rescue-free 24-hour periods (%)

7.5 (19.49)

8.0 (19.48)

4.9 (16.21)

NA

Baseline symptom-free periods (%)

5.1 (15.79)

6.0 (16.20)

2.4 (11.11)

NA

  1. Values are mean (SD) unless otherwise stated.
  2. BD: twice-daily; FEV1: forced expiratory volume in one second; ITT: intent-to-treat; OD: once-daily; SAL: salmeterol; SD: standard deviation; VI: vilanterol.